NCT03986463 (CITaDeL) is a clinical trial of Circulating tumour DNA (ctDNA) in Lung Neoplasms, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

What drugs are being tested in NCT03986463?

Interventions in NCT03986463: Circulating tumour DNA (ctDNA).

What condition does NCT03986463 study?

NCT03986463 studies Lung Neoplasms, Lung Cancer, Neoplasm of Lung, Non Small Cell Lung Cancer.

Is NCT03986463 still recruiting?

NCT03986463 is currently completed. Last updated 18 February 2021.

Last reviewed 2021-02-18 · How we verify

NCT03986463: CITaDeL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

Completed Last updated 18 February 2021

What this trial tests

trial testing Circulating tumour DNA (ctDNA) in Lung Neoplasms in 40 participants. Completed in 31 December 2020.

Timeline

1 May 2019

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 May 2019
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Canada

Drugs / interventions tested

Circulating tumour DNA (ctDNA)

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →
Lung Cancer — all drugs for Lung Cancer →
Neoplasm of Lung — all drugs for Neoplasm of Lung →
Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

18 and older, any sex, with Lung Neoplasms or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observation study in patients with non-small cell lung cancer (NSCLC) starting either cytotoxic chemotherapy or radiation therapy. It will assess changes in circulating tumor DNA (ctDNA) in the days following the initiation of treatment, as well as longitudinal monitoring, to assess the dynamics and value of ctDNA in stage III-IV NSCLC.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, et al · · 2021 · cited 21× · PMID 33918147 · DOI 10.3390/cancers13071675
An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets.
Dotse E, Lim KH, Wang M, Wijanarko KJ, et al · · 2022 · cited 12× · PMID 35207611 · DOI 10.3390/life12020323
Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study.
Breadner DA, Vincent MD, Correa R, Black M, et al · · 2022 · cited 9× · PMID 35124411 · DOI 10.1016/j.lungcan.2022.01.013

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03986463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Last refreshed: 18 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing